SG10201913503VA - Polypeptides inhibiting cd40l - Google Patents

Polypeptides inhibiting cd40l

Info

Publication number: SG10201913503VA
Authority: SG; Singapore
Prior art keywords: polypeptides inhibiting; inhibiting cd40l; cd40l; polypeptides; inhibiting
Prior art date: 2015-11-27

Application number

SG10201913503VA

Other languages

English (en)

Inventor

Els Pattyn

Ariella Van De Sompel

Peter Meerts

Marie-Ange Buyse

Maarten Dewilde

Gerald Beste

Jaromir Vlach

Jonathan Hsu

Original Assignee

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-27

Filing date

2016-11-28

Publication date

2020-03-30

2016-11-28 Application filed by Ablynx Nv filed Critical Ablynx Nv

2020-03-30 Publication of SG10201913503VA publication Critical patent/SG10201913503VA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)

SG10201913503VA 2015-11-27 2016-11-28 Polypeptides inhibiting cd40l SG10201913503VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562260411P	2015-11-27	2015-11-27
US201662345967P	2016-06-06	2016-06-06

Publications (1)

Publication Number	Publication Date
SG10201913503VA true SG10201913503VA (en)	2020-03-30

Family

ID=57471837

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201803976VA SG11201803976VA (en)	2015-11-27	2016-11-28	Polypeptides inhibiting cd40l
SG10201913503VA SG10201913503VA (en)	2015-11-27	2016-11-28	Polypeptides inhibiting cd40l

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201803976VA SG11201803976VA (en)	2015-11-27	2016-11-28	Polypeptides inhibiting cd40l

Country Status (22)

Country	Link
US (1)	US11248055B2 (es)
EP (2)	EP3932945A1 (es)
JP (1)	JP7256011B2 (es)
KR (1)	KR20180080337A (es)
CN (1)	CN108473561B (es)
AU (1)	AU2016360987A1 (es)
BR (1)	BR112018010802A2 (es)
CA (1)	CA3006398A1 (es)
CL (1)	CL2018001400A1 (es)
CO (1)	CO2018005921A2 (es)
DO (1)	DOP2018000128A (es)
EC (1)	ECSP18046820A (es)
GT (1)	GT201800102A (es)
IL (1)	IL259249A (es)
MA (1)	MA43302A (es)
MX (1)	MX2018006377A (es)
PE (1)	PE20181956A1 (es)
PH (1)	PH12018501114A1 (es)
RU (1)	RU2018122255A (es)
SG (2)	SG11201803976VA (es)
TN (1)	TN2018000180A1 (es)
WO (1)	WO2017089618A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL310340A (en)	2016-12-07	2024-03-01	Ablynx Nv	Improved serum albumin binding immunoglobulin single variable domains
EP3571224B1 (en)	2017-01-17	2024-08-07	Ablynx NV	Improved serum albumin binders
SG11201906264YA (en)	2017-01-17	2019-08-27	Ablynx Nv	Improved serum albumin binders
CA3081375A1 (en) *	2017-11-17	2019-05-23	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against pd-l1
CA3163910A1 (en)	2019-12-09	2021-06-17	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
CN114149508B (zh) *	2021-11-25	2023-04-28	苏州普乐康医药科技有限公司	一种结合cd40l的融合蛋白及其应用
US20240415974A1 (en)	2022-12-23	2024-12-19	Ablynx N.V.	Protein-based conjugation carriers
AR131869A1 (es)	2023-02-17	2025-05-07	Ablynx Nv	POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
WO2025133253A2 (en)	2023-12-22	2025-06-26	Ablynx Nv	Protein-based conjugation carriers for intranuclear delivery
WO2025133166A1 (en)	2023-12-22	2025-06-26	Ablynx Nv	Protein-based carriers for site-specific amine conjugation
WO2025235670A1 (en)	2024-05-07	2025-11-13	Eledon Pharmaceuticals, Inc.	Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation
WO2025235683A1 (en)	2024-05-07	2025-11-13	Eledon Pharmaceuticals, Inc.	Methods and compositions for prevention of transplant rejection

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB335768A (en)	1929-10-24	1930-10-02	Jacoviac Maurice	Improvements in protecting devices for gramophone disc records
ATE102631T1 (de)	1988-11-11	1994-03-15	Medical Res Council	Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
SE509359C2 (sv)	1989-08-01	1999-01-18	Cemu Bioteknik Ab	Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DE69330523D1 (de)	1992-08-21	2001-09-06	Vrije Universiteit Brussel Bru	Immunoglobuline ohne leichte ketten
ES2162863T3 (es)	1993-04-29	2002-01-16	Unilever Nv	Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
FR2708622B1 (fr)	1993-08-02	1997-04-18	Raymond Hamers	Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es)	1996-06-27	2008-04-01	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw.	Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
BR9813276A (pt)	1997-10-27	2000-08-22	Unilever Nv	Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
WO1999037681A2 (en)	1998-01-26	1999-07-29	Unilever Plc	Method for producing antibody fragments
CN1316910A (zh)	1998-02-19	2001-10-10	埃克斯西特治疗公司	用于调节淋巴细胞活化的组合物及方法
EP0967284A1 (en)	1998-05-28	1999-12-29	Pfizer Limited	Phosphodiesterases
BR9916765A (pt)	1999-01-05	2001-09-25	Unilever Nv	Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico
WO2000043507A1 (en)	1999-01-19	2000-07-27	Unilever Plc	Method for producing antibody fragments
WO2000046383A2 (en)	1999-02-05	2000-08-10	Rijksuniversiteit Leiden	Method of modulating metabolite biosynthesis in recombinant cells
AU784108B2 (en)	1999-03-15	2006-02-02	University Of British Columbia, The	Methods and reagents for modulating cholesterol levels
AP1447A (en)	1999-04-22	2005-08-12	Unilever Plc	Inhibition of viral infection using monovalent antigen-binding proteins.
CA2375781A1 (en)	1999-06-18	2000-12-28	Cv Therapeutics, Inc.	Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abci
EP1198572A2 (en)	1999-08-02	2002-04-24	Keygene N.V.	Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
GB9922124D0 (en)	1999-09-17	1999-11-17	Pfizer Ltd	Phosphodiesterase enzymes
US6479280B1 (en)	1999-09-24	2002-11-12	Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de)	1999-11-18	2001-05-23	Bayer Ag	GABA-B-Rezeptoren
ES2331051T3 (es)	1999-11-29	2009-12-21	Bac Ip B.V.	Inmovilizacion de moleculas de union de antigenos de un dominio.
US7358096B1 (en)	1999-11-29	2008-04-15	Conopco, Inc.	Immobilisation of proteins
JP2003518075A (ja)	1999-12-24	2003-06-03	ジェネンテック・インコーポレーテッド	生理活性化合物の消失半減期延長のための方法及び組成物
EP1134231B1 (en)	2000-03-14	2009-04-15	Unilever N.V.	Antibody heavy chain variable domains against human dietary lipases, and their uses
GB0006398D0 (en)	2000-03-16	2000-05-03	Novartis Ag	Organic compounds
US20030190598A1 (en)	2000-05-26	2003-10-09	Jasmid Tanha	Single-domain antigen-binding antibody fragments derived from llama antibodies
EP1360207B1 (en)	2000-12-13	2011-06-22	Bac Ip B.V.	Protein arrays of camelid heavy-chain immunoglobulin variable domains
CA2440582A1 (en)	2001-03-09	2002-10-03	Dyax Corp.	Serum albumin binding moieties
US20060073141A1 (en)	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
WO2003002609A2 (en)	2001-06-28	2003-01-09	Domantis Limited	Dual-specific ligand and its use
WO2003025020A1 (en)	2001-09-13	2003-03-27	Institute For Antibodies Co., Ltd.	Method of constructing camel antibody library
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
AU2002351896A1 (en)	2001-12-11	2003-06-23	Ablynx N.V.	Method for displaying loops from immunoglobulin domains in different contexts
US20050037358A1 (en)	2001-12-21	2005-02-17	Serge Muyldermans	Method for cloning of variable domain sequences
WO2003055527A2 (en)	2002-01-03	2003-07-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Immunoconjugates useful for treatment of tumours
AU2003284891A1 (en)	2002-10-23	2004-05-13	Ludwig Institute For Cancer Research	A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
AU2003286002B2 (en)	2002-11-08	2011-06-16	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060228355A1 (en)	2003-11-07	2006-10-12	Toon Laeremans	Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
JP2006519763A (ja)	2002-11-08	2006-08-31	アブリンクスエン．ヴェー．	治療用ポリペプチドの投与法およびそのためのポリペプチド
EP2390270A1 (en)	2003-01-10	2011-11-30	Ablynx N.V.	Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
US7461263B2 (en)	2003-01-23	2008-12-02	Unspam, Llc.	Method and apparatus for a non-revealing do-not-contact list system
WO2005018629A1 (en)	2003-08-12	2005-03-03	Yarbrough William M	Treatment for acne vulgaris and method of use
US7563443B2 (en) *	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP5113523B2 (ja)	2004-10-13	2013-01-09	アブリンクスナームローゼフェンノートシャップ	アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド
WO2006079372A1 (en)	2005-01-31	2006-08-03	Ablynx N.V.	Method for generating variable domain sequences of heavy chain antibodies
EP2949668B1 (en)	2005-05-18	2019-08-14	Ablynx N.V.	Improved nanobodies tm against tumor necrosis factor-alpha
BRPI0609797B8 (pt)	2005-05-20	2021-05-25	Ablynx Nv	nanocorpos melhorados para o tratamento de desordens mediadas por agregação
AU2007285695B2 (en)	2006-08-18	2012-05-24	Ablynx N.V.	Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
US20080267949A1 (en)	2006-12-05	2008-10-30	Ablynx N.V.	Peptides capable of binding to serum proteins
US20110118185A9 (en)	2007-02-21	2011-05-19	Ablynx N.V.	Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
EP2125894B1 (en)	2007-03-22	2018-12-19	Biogen MA Inc.	Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
MX2009012650A (es)	2007-05-24	2010-02-18	Ablynx Nv	Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
CN102089325A (zh)	2008-04-17	2011-06-08	埃博灵克斯股份有限公司	能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
JP5723769B2 (ja) *	2008-06-03	2015-05-27	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリン及びその使用
EP3309176B1 (en) *	2009-12-14	2025-10-01	Ablynx N.V.	Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
EP2654792A4 (en) *	2010-12-22	2016-05-11	Abbvie Inc	HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
DK2723769T4 (da)	2011-06-23	2022-09-05	Ablynx Nv	Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
EP3466972A1 (en) *	2011-06-23	2019-04-10	Ablynx NV	Serum albumin binding proteins
EA027160B1 (ru)	2011-08-17	2017-06-30	Глаксо Груп Лимитед	Модифицированные белки и пептиды
SMT202000091T1 (it)	2011-10-13	2020-05-08	Bristol Myers Squibb Co	Polipeptidi anticorpali che antagonizzano cd40l
CN105814082A (zh)	2013-09-26	2016-07-27	埃博灵克斯股份有限公司	双特异性纳米抗体
CN106132429A (zh) *	2014-03-19	2016-11-16	百时美施贵宝公司	使用针对cd40l的域抗体治疗移植物排斥的方法
CR20180097A (es)	2015-07-14	2018-05-25	Immunext Inc	Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
US10669343B2 (en)	2015-08-05	2020-06-02	Janssen Biotech, Inc.	Anti-CD154 antibodies and methods of using them

2016
- 2016-11-28 RU RU2018122255A patent/RU2018122255A/ru unknown
- 2016-11-28 TN TNP/2018/000180A patent/TN2018000180A1/en unknown
- 2016-11-28 EP EP21179221.3A patent/EP3932945A1/en not_active Withdrawn
- 2016-11-28 SG SG11201803976VA patent/SG11201803976VA/en unknown
- 2016-11-28 SG SG10201913503VA patent/SG10201913503VA/en unknown
- 2016-11-28 JP JP2018527745A patent/JP7256011B2/ja active Active
- 2016-11-28 US US15/778,677 patent/US11248055B2/en active Active
- 2016-11-28 WO PCT/EP2016/079048 patent/WO2017089618A1/en not_active Ceased
- 2016-11-28 KR KR1020187018169A patent/KR20180080337A/ko not_active Withdrawn
- 2016-11-28 EP EP16805359.3A patent/EP3380517B1/en active Active
- 2016-11-28 MA MA043302A patent/MA43302A/fr unknown
- 2016-11-28 PE PE2018001013A patent/PE20181956A1/es unknown
- 2016-11-28 BR BR112018010802A patent/BR112018010802A2/pt not_active Application Discontinuation
- 2016-11-28 MX MX2018006377A patent/MX2018006377A/es unknown
- 2016-11-28 AU AU2016360987A patent/AU2016360987A1/en not_active Abandoned
- 2016-11-28 CA CA3006398A patent/CA3006398A1/en not_active Abandoned
- 2016-11-28 CN CN201680068704.XA patent/CN108473561B/zh active Active
2018
- 2018-05-09 IL IL259249A patent/IL259249A/en unknown
- 2018-05-21 GT GT201800102A patent/GT201800102A/es unknown
- 2018-05-22 DO DO2018000128A patent/DOP2018000128A/es unknown
- 2018-05-24 CL CL2018001400A patent/CL2018001400A1/es unknown
- 2018-05-25 PH PH12018501114A patent/PH12018501114A1/en unknown
- 2018-06-08 CO CONC2018/0005921A patent/CO2018005921A2/es unknown
- 2018-06-21 EC ECSENADI201846820A patent/ECSP18046820A/es unknown

Also Published As

Publication number	Publication date
MA43302A (fr)	2021-03-17
WO2017089618A1 (en)	2017-06-01
EP3380517B1 (en)	2021-08-04
MX2018006377A (es)	2018-09-05
SG11201803976VA (en)	2018-06-28
PH12018501114A1 (en)	2019-01-28
JP2019504822A (ja)	2019-02-21
ECSP18046820A (es)	2018-07-31
CN108473561B (zh)	2022-12-16
RU2018122255A3 (es)	2020-04-06
IL259249A (en)	2018-07-31
KR20180080337A (ko)	2018-07-11
CO2018005921A2 (es)	2018-06-20
CN108473561A (zh)	2018-08-31
CA3006398A1 (en)	2017-06-01
EP3380517A1 (en)	2018-10-03
DOP2018000128A (es)	2018-09-30
US20180355050A1 (en)	2018-12-13
GT201800102A (es)	2019-08-15
CL2018001400A1 (es)	2018-10-26
PE20181956A1 (es)	2018-12-17
AU2016360987A1 (en)	2018-06-07
RU2018122255A (ru)	2019-12-19
TN2018000180A1 (en)	2019-10-04
BR112018010802A2 (pt)	2018-11-27
US11248055B2 (en)	2022-02-15
EP3932945A1 (en)	2022-01-05
JP7256011B2 (ja)	2023-04-11

Publication	Publication Date	Title
ZA201802261B (en)	2022-10-26	Polypeptides
IL255767A (en)	2018-01-31	New polypeptides
IL254577A0 (en)	2017-11-30	polypeptides
IL259249A (en)	2018-07-31	cd40l inhibitory polypeptides
GB201520559D0 (en)	2016-01-06	Peptides
IL260182A (en)	2018-07-31	Polypeptides to inhibit complement activation
ZA201704366B (en)	2022-09-28	Il-17a-binding polypeptides
SG11201706882VA (en)	2017-09-28	Polypeptides
GB201520539D0 (en)	2016-01-06	Peptides
GB201520536D0 (en)	2016-01-06	Peptides
GB201520546D0 (en)	2016-01-06	Peptides
GB201520543D0 (en)	2016-01-06	Peptides
GB201520563D0 (en)	2016-01-06	Peptides
GB201520562D0 (en)	2016-01-06	Peptides
GB201520550D0 (en)	2016-01-06	Peptides
GB201520564D0 (en)	2016-01-06	Peptides
GB201520544D0 (en)	2016-01-06	Peptides
GB201520541D0 (en)	2016-01-06	Peptides
GB201520548D0 (en)	2016-01-06	Peptides
GB201520542D0 (en)	2016-01-06	Peptides
GB201520557D0 (en)	2016-01-06	Peptides
HK1262825A1 (en)	2020-01-24	Polypeptides inhibiting cd40l
GB201515245D0 (en)	2015-10-14	Novel polypeptides
GB201520535D0 (en)	2016-01-06	Peptides
GB201520556D0 (en)	2016-01-06	Peptides